Semaglutide weight loss on the NHS: who qualifies, what to expect, and what to do if you don't

Does the NHS prescribe semaglutide for weight loss, and who meets the criteria?

The short answer is yes, but the criteria are specific. NICE recommended semaglutide (Wegovy) for weight management in Technology Appraisal 875, published in 2023. Under that guidance, NHS patients need a BMI of 35 or above alongside at least one weight-related condition, or a BMI between 30 and 34.9 if specialist-referral criteria are met. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, those thresholds are typically 2.5 kg/m² lower.

There is also a treatment-duration limit that surprises many people: NICE recommends semaglutide for a maximum of two years, and it should be used within a specialist weight management service that provides multidisciplinary support, not just the medicine. If less than 5% of body weight is lost after six months at the maintenance dose, continuing treatment should be reviewed.

From 1 April 2026, GP practices in England can prescribe tirzepatide under a new contract arrangement, but practice participation is optional and varies widely. For semaglutide specifically, the NHS route remains specialist-led for now. Waiting lists in many areas are long. The full picture of NHS semaglutide availability is covered in more detail separately, because the answer genuinely differs depending on where in the country you live.

What does semaglutide actually do, and what did the clinical trials show?

Semaglutide works on a receptor in the gut and brain called the GLP-1 receptor. By activating it, the medicine slows how quickly the stomach empties and increases the feeling of fullness after eating, which naturally reduces how much most people want to eat day to day. It is a once-weekly subcutaneous injection, typically starting at 0.25mg and titrated by the prescriber over several months up to a maintenance dose, 2.4mg has been the standard, with 7.2mg now also approved by the MHRA.

The pivotal trial evidence comes from the STEP programme. In the STEP 1 study, published in the New England Journal of Medicine, adults treated with semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks, compared with around 2.4% in the placebo group. That is a meaningful difference in absolute terms. More recently, a 7.2mg maintenance dose has been studied, with trial data reporting approximately 20.7% average weight loss over 72 weeks, bringing it closer to the results seen with tirzepatide at its highest dose. For a deeper look at what the trial data says, the evidence page sets out the numbers in full context.

Side effects are mostly gastrointestinal, nausea, loose stools, constipation and reflux are the ones people mention most. They tend to be worst in the first few weeks or after a dose increase, then settle for most people. Anyone experiencing severe, persistent stomach pain that spreads to the back should get medical help promptly; the MHRA highlighted acute pancreatitis as an infrequent but serious risk in a Drug Safety Update in January 2026.

If NHS access isn't available to me right now, what is the private route?

Private prescribing of Wegovy is legal, regulated and available now. A registered prescriber (not a GP referral, not a waiting list) assesses your medical history, confirms you meet the licensed criteria, and issues a prescription if it is clinically appropriate. The prescription is then dispensed by a GPhC-registered pharmacy, which you can check on the GPhC register. That check takes under a minute: search by pharmacy name or registration number and look for a current, active entry.

That verification step matters more than it might seem. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online, some of which have caused serious harm. Fake pens have no clinical oversight behind them and no genuine supply chain. A legitimate private service will always require clinical assessment, a prescriber who reviews your answers and decides suitability. It will not offer these medicines without one.

At nume, a GPhC-registered Independent Prescriber personally reviews every consultation the same day it is submitted. There are no subscriptions and no hidden fees. Our GPhC premises registration is 9012878, which you can verify directly on the register. If you're weighing up the costs involved in private Wegovy treatment, that page covers what is typically included (and what often isn't) in market pricing. You can also read more about where to source semaglutide for weight loss safely before making any decision.

Is semaglutide on the NHS the same medicine as the private version?

Yes. Whether prescribed through an NHS specialist service or by a private prescriber, the medicine itself is the same: semaglutide in the Wegovy formulation, manufactured by Novo Nordisk and dispensed through the licensed UK supply chain. There is no NHS-only version and no private-only version. What differs is the route to obtaining it, the criteria applied, and the support structure around the prescription.

One thing worth knowing: Ozempic is also semaglutide, but it is licensed for type 2 diabetes management, not weight loss. The two are not interchangeable for the purposes of weight management, and prescribing Ozempic for weight loss falls outside its licence. Rybelsus (oral semaglutide) is also licensed for diabetes only. The weight-loss tablet formulation is the Wegovy tablet, which received MHRA approval in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. If you're curious about how microdose semaglutide works and whether it might suit you, that page walks through the process in detail, or you can explore the practical steps to access Wegovy and the broader range of weight-loss treatment options available through a clinical consultation.